Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 946-952

  Angeby K A ^a   Jureen, P ^b   Giske, C G ^a   Chryssanthou, E ^a   Sturegard E ^c   Nordvall, M ^d   Johansson, A G ^d   Werngren, J ^b   Kahlmeter, G ^e,f   Hoffner, S E ^b   Schon T ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e Vaxjo Hospital   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Ciprofloxacin; Levofloxacin; Moxifloxacin; Ofloxacin; Susceptibility testing

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; DRUG DISTRIBUTION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 77953726929     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq091     Document Type: Article

References (22)

1. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2008. http://whqlibdoc.who.int/publications/2008/9789241 547581_eng.pdf (17 February 2010, date last accessed).
2. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A. NCCLS, Wayne, PA, USA, 2003.
3. WHO. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. 2008. http://www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf (17 February 2010, date last accessed).
4. Schön T, Juréen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
5. Kahlmeter G, Brown DF, Goldstein FW et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006; 12: 501-3.
6. Kim J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-9.
7. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1998; 137: 1217-22.
8. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
9. TB Alliance. TB Alliance Portfolio: Moxifloxacin. http://www.tballiance.org/new/portfolio/html-portfolio-item.php?id=17 (11 October 2009, date last accessed).
10. Laszlo A, Rahman M, Espinal M et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational reference laboratory network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-56.
11. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis Surveillance in Europe 2007. Stockholm: European Centre for Disease Prevention and Control, 2009.
12. Peloquin CA, Hadad DJ, Dutra Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.
13. Global Alliance for TB Drug Development (TB Alliance). Handbook of Anti-Tuberculosis Agents. Tuberculosis 2008; 88: 85-167.
14. Rastogi N, Goh KS, Bryskier A et al. In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculosis drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 1610-6.
15. Rodríguez JC, Ruiz M, López M et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-7.
16. Ruiz-Serrano MJ, Alcalá L, Martínez L et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
17. Rüsch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
18. Springer B, Lucke K, Calligaris-Maibach R et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-80.
19. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
20. Gunderson BW, Ross GH, Ibrahim KH et al. What dowe really know about antibiotic pharmacodynamics? Pharmacotherapy 2001; 21: 302S-18S.
21. Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 2008; 88 Suppl 1: S75-83.
22. Johnson JL, Hadad DJ, Boom WH et al. Early and extended bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.